Literature DB >> 35687178

GLP-1 receptor nitration contributes to loss of brain pericyte function in a mouse model of diabetes.

Joseph Bailey1, Maha Coucha2, Deanna R Bolduc1, Faith N Burnett1, Amy C Barrett1, Mark Ghaly1, Mohammed Abdelsaid3.   

Abstract

AIMS/HYPOTHESIS: We have previously shown that diabetes causes pericyte dysfunction, leading to loss of vascular integrity and vascular cognitive impairment and dementia (VCID). Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs), used in managing type 2 diabetes mellitus, improve the cognitive function of diabetic individuals beyond glycaemic control, yet the mechanism is not fully understood. In the present study, we hypothesise that GLP-1 RAs improve VCID by preventing diabetes-induced pericyte dysfunction.
METHODS: Mice with streptozotocin-induced diabetes and non-diabetic control mice received either saline (NaCl 154 mmol/l) or exendin-4, a GLP-1 RA, through an osmotic pump over 28 days. Vascular integrity was assessed by measuring cerebrovascular neovascularisation indices (vascular density, tortuosity and branching density). Cognitive function was evaluated with Barnes maze and Morris water maze. Human brain microvascular pericytes (HBMPCs), were grown in high glucose (25 mmol/l) and sodium palmitate (200 μmol/l) to mimic diabetic conditions. HBMPCs were treated with/without exendin-4 and assessed for nitrative and oxidative stress, and angiogenic and blood-brain barrier functions.
RESULTS: Diabetic mice treated with exendin-4 showed a significant reduction in all cerebral pathological neovascularisation indices and an improved blood-brain barrier (p<0.05). The vascular protective effects were accompanied by significant improvement in the learning and memory functions of diabetic mice compared with control mice (p<0.05). Our results showed that HBMPCs expressed the GLP-1 receptor. Diabetes increased GLP-1 receptor expression and receptor nitration in HBMPCs. Stimulation of HBMPCs with exendin-4 under diabetic conditions decreased diabetes-induced vascular inflammation and oxidative stress, and restored pericyte function (p<0.05). CONCLUSIONS/
INTERPRETATION: This study provides novel evidence that brain pericytes express the GLP-1 receptor, which is nitrated under diabetic conditions. GLP-1 receptor activation improves brain pericyte function resulting in restoration of vascular integrity and BBB functions in diabetes. Furthermore, the GLP-1 RA exendin-4 alleviates diabetes-induced cognitive impairment in mice. Restoration of pericyte function in diabetes represents a novel therapeutic target for diabetes-induced cerebrovascular microangiopathy and VCID.
© 2022. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.

Entities:  

Keywords:  Cognitive function; Diabetes; GLP-1 receptor; Nitration; Pericytes; Vascular cognitive impairment and dementia

Mesh:

Substances:

Year:  2022        PMID: 35687178     DOI: 10.1007/s00125-022-05730-5

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.460


  43 in total

Review 1.  The role of pericytes in blood-vessel formation and maintenance.

Authors:  Gabriele Bergers; Steven Song
Journal:  Neuro Oncol       Date:  2005-10       Impact factor: 12.300

Review 2.  Investigational treatments for Type 2 diabetes mellitus: exenatide and liraglutide.

Authors:  Claudio González; Valeria Beruto; Guillermo Keller; Silvina Santoro; Guillermo Di Girolamo
Journal:  Expert Opin Investig Drugs       Date:  2006-08       Impact factor: 6.206

3.  [Management of hyperglycaemia of type 2 diabetes. Paradigm change according to the ADA-EASD consensus report 2018].

Authors:  A J Scheen; N Paquot
Journal:  Rev Med Liege       Date:  2018-12

4.  Liraglutide prevents cognitive decline in a rat model of streptozotocin-induced diabetes independently from its peripheral metabolic effects.

Authors:  Caterina Palleria; Antonio Leo; Francesco Andreozzi; Rita Citraro; Michelangelo Iannone; Rosangela Spiga; Giorgio Sesti; Andrew Constanti; Giovambattista De Sarro; Franco Arturi; Emilio Russo
Journal:  Behav Brain Res       Date:  2017-01-03       Impact factor: 3.332

5.  Vascular contributions to cognitive impairment and dementia (VCID).

Authors:  M Paul Murphy; Roderick A Corriveau; Donna M Wilcock
Journal:  Biochim Biophys Acta       Date:  2016-02-26

Review 6.  Vascular complications in diabetes: old messages, new thoughts.

Authors:  Josephine M Forbes; Amelia K Fotheringham
Journal:  Diabetologia       Date:  2017-07-19       Impact factor: 10.122

7.  Exendin-4 improves cardiovascular function and survival in flow-induced pulmonary hypertension.

Authors:  Jun-Neng Roan; Chih-Hsin Hsu; Shih-Yuan Fang; Hung-Wen Tsai; Chwan-Yau Luo; Chien-Chi Huang; Chen-Fuh Lam
Journal:  J Thorac Cardiovasc Surg       Date:  2017-11-07       Impact factor: 5.209

Review 8.  Impact of Metabolic Diseases on Cerebral Circulation: Structural and Functional Consequences.

Authors:  Maha Coucha; Mohammed Abdelsaid; Rebecca Ward; Yasir Abdul; Adviye Ergul
Journal:  Compr Physiol       Date:  2018-03-25       Impact factor: 9.090

Review 9.  The physiology of glucagon-like peptide 1.

Authors:  Jens Juul Holst
Journal:  Physiol Rev       Date:  2007-10       Impact factor: 37.312

10.  Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the action to control cardiovascular risk in diabetes-memory in diabetes (ACCORD-MIND) trial.

Authors:  Tali Cukierman-Yaffe; Hertzel C Gerstein; Jeff D Williamson; Ronald M Lazar; Laura Lovato; Michael E Miller; Laura H Coker; Anne Murray; Mark D Sullivan; Santica M Marcovina; Lenore J Launer
Journal:  Diabetes Care       Date:  2009-02       Impact factor: 17.152

View more
  1 in total

1.  Calpain Inhibitor Calpeptin Improves Alzheimer's Disease-Like Cognitive Impairments and Pathologies in a Diabetes Mellitus Rat Model.

Authors:  Min Li; Siqi Zhou; Gege Wang; Luyao Qiao; Shouqin Yi; Tianpei Li; Xin Pan; Xu Liu; Zhenyu Tang
Journal:  Neurotox Res       Date:  2022-08-26       Impact factor: 3.978

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.